Is RIGL a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

388 people get RIGL articles and Market Currents by email alert.

Get email alerts on RIGL »

HEADLINES:

A Journey To Add Biotech To The Portfolio
Gregory Stuckey • Sat, May 18 • 8 Comments
Rigel Announces First Quarter 2013 Financial Results

PR Newswire (May 7, 2013)
Small Pharma Watch List: Week Of April 8, 2013
Chemistfrog • Mon, Apr 8 • 8 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Mon, Apr 8 • 1 Comment
AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis

PR Newswire (Apr 5, 2013)
Pivotal Phase III Trial Data Ahead For 3 Development-Stage Small Pharma Companies
Chemistfrog • Tue, Mar 26 • 4 Comments
Rigel Pharmaceuticals: 7 Reasons To Buy This $7 Drug Stock
Bret Jensen • Wed, Mar 6 • 2 Comments
Rigel Announces Fourth Quarter and Year End 2012 Financial Results

PR Newswire (Mar 5, 2013)
Rigel Announces Participation at Two Investor Conferences

PR Newswire (Feb 28, 2013)
Rigel to Present at BIO CEO & Investor Conference

PR Newswire (Feb 7, 2013)
Rigel to Focus on Extensive Clinical Pipeline at Upcoming J.P. Morgan Presentation

PR Newswire (Jan 3, 2013)
Rigel Recovers On 2013 Hope For Its Rheumatoid Arthritis Drug
Brian L. Wilson • Wed, Dec 19, 2012 • 1 Comment
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Fri, Dec 14, 2012 • 1 Comment
The Occultation Of Rigel Pharmaceuticals
Stephen Simpson • Thu, Dec 13, 2012 • 13 Comments
AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis

PR Newswire (Dec 13, 2012)
Pfizer's Pipeline Offers Diversified Product Portfolio
Horizon Investments • Tue, Dec 11, 2012 • 2 Comments
Rigel to Present at Jefferies 2012 Global Healthcare Conference in London

PR Newswire (Nov 8, 2012)
Rigel Announces Third Quarter 2012 Financial Results

PR Newswire (Nov 6, 2012)
Rigel Announces Pricing Of Public Offering Of Common Stock

PR Newswire (Oct 3, 2012)
Rigel Announces Proposed Public Offering Of Common Stock

PR Newswire (Oct 2, 2012)

To learn more about Seeking Alpha Pro, click here.

Rigel Pharmaceuticals: 7 Reasons To Buy This $7 Drug Stock
Bret Jensen • Wed, Mar 6 • 2 Comments
Rigel Recovers On 2013 Hope For Its Rheumatoid Arthritis Drug
Brian L. Wilson • Wed, Dec 19, 2012 • 1 Comment
The Occultation Of Rigel Pharmaceuticals
Stephen Simpson • Thu, Dec 13, 2012 • 13 Comments
Rigel Pharma: Key RA Drug Data Expected Late 2012 Through H1 2013
Mike Havrilla • Tue, Sep 4, 2012 • 1 Comment
The Waiting May Be The Hard Part For Rigel Pharmaceuticals
Stephen Simpson • Tue, Aug 28, 2012 • 1 Comment
Rigel's Drug Trials Offer Upside Through 2013
Todd Campbell • Tue, Jul 31, 2012
Rigel Pharma Has More Room To Run
Stephen Simpson • Mon, Feb 6, 2012 • 1 Comment
Rigel Refuels R&D in $130M Offering
The Burrill Report • Sun, May 29, 2011
Rigel Pharma: The Importance of Knowing Your Stock
Stone Fox Capital • Wed, Jul 29, 2009 • 8 Comments
Rigel Pharmaceuticals: A Game Changer in the Works?
Dr. Anthony • Sun, Jun 28, 2009 • 2 Comments
Rigel's Punishment May Prove Short-Sighted
EP Vantage • Fri, Oct 31, 2008 • 1 Comment

A Journey To Add Biotech To The Portfolio
Gregory Stuckey • Sat, May 18 • 8 Comments
Small Pharma Watch List: Week Of April 8, 2013
Chemistfrog • Mon, Apr 8 • 8 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Mon, Apr 8 • 1 Comment
Pivotal Phase III Trial Data Ahead For 3 Development-Stage Small Pharma Companies
Chemistfrog • Tue, Mar 26 • 4 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Fri, Dec 14, 2012 • 1 Comment
Pfizer's Pipeline Offers Diversified Product Portfolio
Horizon Investments • Tue, Dec 11, 2012 • 2 Comments
4 Low-Debt Pharmaceutical Stocks Backed By Analysts
ZetaKap • Wed, Aug 29, 2012 • 2 Comments
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts During The Next 3 - 9 Months
Markus Aarnio • Mon, Aug 20, 2012 • 4 Comments
Reasons To Own AbbVie After Abbott Splits In Two
Todd Campbell • Tue, Aug 14, 2012 • 13 Comments
AstraZeneca Offsets Generic Risk With New Drugs
Todd Campbell • Thu, Aug 2, 2012 • 5 Comments
Vertex's Cystic Fibrosis Pipeline Offers Sales Upside
Todd Campbell • Wed, Aug 1, 2012 • 3 Comments
3 Analyst-Backed Pharmaceutical Stocks With Great Projections
ZetaKap • Wed, Aug 1, 2012 • 7 Comments
What This News Means For Healthcare Stocks
Timeless Wealth • Tue, Jun 19, 2012
5 High Growth Pharmaceutical Stocks Holding Analysts' Confidence
ZetaKap • Wed, Jun 13, 2012 • 5 Comments
Chelsea: A Short-Term Buying Opportunity
Kevin CC • Wed, May 23, 2012 • 21 Comments
6 Low Debt Pharmaceutical Stocks Rated Buy Or Better
ZetaKap • Mon, May 14, 2012 • 2 Comments
Pfizer: Is 8 Really Enough?
Kevin CC • Fri, May 11, 2012
Oral Rheumatoid Arthritis Market Remains Open As FDA Questions Efficacy Of Pfizer's Pill
Kevin CC • Wed, May 9, 2012 • 4 Comments
VIX - Options Volatility Sonar: Tuesday Recap And Apple Earnings
Erick McKitterick • Tue, Apr 24, 2012 • 8 Comments
5 Biotech Stocks To Boost Your Portfolio
Ry Frank • Sun, Apr 22, 2012

There are no Transcripts on RIGL.

Rigel Announces First Quarter 2013 Financial Results

PR Newswire (May 7, 2013)
AstraZeneca's Arthritis Pill Disappoints in Late-Stage Trial

at Fox Business (Apr 5, 2013)
AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis

PR Newswire (Apr 5, 2013)
Rigel Announces Fourth Quarter and Year End 2012 Financial Results

PR Newswire (Mar 5, 2013)
Rigel Announces Participation at Two Investor Conferences

PR Newswire (Feb 28, 2013)
Rigel to Present at BIO CEO & Investor Conference

PR Newswire (Feb 7, 2013)
Rigel to Focus on Extensive Clinical Pipeline at Upcoming J.P. Morgan Presentation

PR Newswire (Jan 3, 2013)
AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis

PR Newswire (Dec 13, 2012)
Rigel to Present at Jefferies 2012 Global Healthcare Conference in London

PR Newswire (Nov 8, 2012)
Rigel Announces Third Quarter 2012 Financial Results

PR Newswire (Nov 6, 2012)
Movers & Shakers: Wednesday’s biggest gaining and declining stocks

at MarketWatch.com (Oct 3, 2012)
Rigel Announces Pricing Of Public Offering Of Common Stock

PR Newswire (Oct 3, 2012)
Rigel Announces Proposed Public Offering Of Common Stock

PR Newswire (Oct 2, 2012)
Rigel to Present at UBS Global Life Sciences Conference

PR Newswire (Sep 17, 2012)
Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus

PR Newswire (Sep 5, 2012)
Rigel Announces Second Quarter 2012 Financial Results

PR Newswire (Aug 7, 2012)
AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma

PR Newswire (Jun 19, 2012)
Rigel Announces Participation at Two Investor Conferences

PR Newswire (May 31, 2012)
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease

PR Newswire (May 16, 2012)
Rigel Announces First Quarter 2012 Financial Results

PR Newswire (May 1, 2012)

RIGL vs. ETF Alternatives

Company Description

Currently, there's no company description for RIGL.

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 7, 12:38 PM Rigel Pharmaceuticals (RIGL -2.7%) slips after reporting an in-line Q1, but losses were higher Y/Y due to an absence of contract revenue and higher operating costs. Total operating expenses were $25.7M for the quarter, compared to $24.1M in Q112. The increase was primarily due to R&D expense related to ongoing studies of R348, its topical ophthalmic JAK/SYK inhibitor program for chronic dry eye, and R343, an inhaled SYK inhibitor program for asthma. Comment! [Healthcare, On the Move, Earnings]
Tuesday, May 7, 7:45 AM Rigel Pharmaceuticals (RIGL): Q1 EPS of -$0.29 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, May 7, 12:05 AM Notable earnings before Tuesday’s open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC 2 Comments [Earnings]
Monday, May 6, 5:30 PM Notable earnings before Tuesday's open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC Comment! [Earnings]
Friday, April 5, 5:38 PM After-hours top gainers, as of 5:15 p.m.: GOL +6%. PSUN +6%. MEET +3.5%. RIGL +3.3%. CIA +2.5%.
After-hours top losers: HNR -7.6%. BTH -6.3%. SYRG -6%. MM -5.7%. EVC -4.5%. Comment! [On the Move]
Friday, April 5, 9:10 AM Premarket gainers: XIDE +31%. NIHD +10%. NVAX +5%.
Losers: RIGL -36%. FFIV -18%. RDWR -18%. JNPR -7%. CBMX -5%. Comment! [On the Move]
Friday, April 5, 8:58 AM Rigel Pharmaceuticals (RIGL) plummets before the bell after adverse side effects were observed in a late-stage clinical trial of AstraZeneca's (AZN) rheumatoid arthritis drug fostamatinib. It also appears the drug may be inferior to AbbVie's Humira in terms of efficacy. The drug is licensed from Rigel whose shares are -35% premarket on heavy volume. Comment! [Healthcare, On the Move]
Thursday, March 7, 5:54 PM After-hours top gainers, as of 5:15 p.m.: P +19%. AMBA +9%. PETS +7%. PANL +6%. RIGL +5%.
After-hours top losers: MED -9%. ZQK -9%. AVG -6%. SKUL -6%. ANGO -5%. 1 Comment [On the Move]
Tuesday, March 5, 2:27 PM Rigel Pharmaceuticals (RIGL +5.4%) moves up today with a solid Q4 earnings beat on narrower losses. Piper Jaffray notes that the company's key drug fostamatinib's Phase 3 studies look encouraging, and will provide an upside to stock performance over the near term. JP Morgan agrees, saying that rheumatoid arthritis represents a huge and growing worldwide annual market of nearly $13B, and fostamatinib could emerge as a meaningful player in this space. Comment! [Healthcare, Earnings, On the Move]
Tuesday, March 5, 7:38 AM Rigel Pharmaceuticals (RIGL): Q4 EPS of -$0.30 beats by $0.02. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, December 14, 2012, 12:45 PM Midday top 10 gainers: ALIM +30%. STXS +19%. QUAD +18%. RIGL +15%. CHOP +19%. OTT +16%. ZAZA +13%. ALU +12%. AXR +11%. SZYM +11%.
Midday top 10 Losers: YOD -23%. LPTN -18%. CYTX -15%. ZQK -15%. BBY -15%. USNA -11%. PAY -10%. MEIP -9%. LAS -9%. VGZ -10%. Comment!
Thursday, December 13, 2012, 12:45 PM Midday top 10 gainers: ONCY +51%. TELK +23%. PRGN +21%. GBR +17%. SDBT +16%. SAM +15%. BBY +15%. CLWR +14%. ZAGG +14%. TROV +13%.
Midday top 10 Losers: RIGL -35%. EVI -31%. HRG -26%. PTIE -19%. CBMX -18%. OSN -15%. MEIP -13%. DQ -12%. CSUN -12%. ALLT -11%. Comment! [On the Move]
Thursday, December 13, 2012, 9:10 AM Premarket gainers: TELK +28%. ONCY +22%. BBY +17%. CLWR +13%. CVS +5%. TSL +5%.
Losers: RIGL -33%. HRG -26%. Comment! [On the Move]
Thursday, December 13, 2012, 9:06 AM Rigel Pharmaceuticals (RIGL) craters 34% following news that fostamatinib, which it's developing with AstraZeneca, was inferior to Abbott Labs' Humira in controlling rheumatoid arthritis in a Phase IIb trial. Comment! [Healthcare, On the Move]
Tuesday, November 6, 2012, 8:48 AM Rigel Pharmaceuticals (RIGL): Q3 EPS of -$0.36 beats by $0.02. (PR) Comment! [Earnings, Healthcare]
Wednesday, October 3, 2012, 9:48 AM Rigel Pharmaceuticals (RIGL) sinks 7.3% to $9.58 after pricing an offering of 13.685M shares at $9.50 each, resulting in gross proceeds of $130M. The underwriters have a 30-day option to buy up to 2.05M extra shares to cover overallotments. (PR) Comment! [Healthcare, On the Move]

Ryan Mallory
Fuinhaz Setups for April 8 2013 | $AMRN $BCRX $FSLR $GLUU $PERI $RIGL $SRPT $SVA $ZNGA | http://bit.ly/10MTLwT
Apr 8, 9:11 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
4 Low-Debt Pharmaceutical Stocks Backed By Analysts http://bit.ly/Ou7S51 $ASTX $ECYT $IPXL $RIGL @ZetaKap
8/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
3 Analyst-Backed Pharmaceutical Stocks With Great Projections http://bit.ly/NTzNgg $AEGR $KERX $RIGL @ZetaKap
8/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 High Growth Pharmaceutical Stocks Holding Analysts' Confidence http://bit.ly/MEQjNU $AEGR $HZNP $KERX $PCRX $RIGL @ZetaKap
6/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
$$ 6 Low Debt Pharmaceutical Stocks Rated Buy Or Better http://bit.ly/L0WSca $ASTX $ECTE $IPXL $KERX $RIGL $VTUS @ZetaKap #pharma
5/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
$$ Just posted: 6 Low Debt Pharmaceutical Stocks Rated Buy Or Better http://bit.ly/L0WSca $ASTX $ECTE $IPXL $KERX $RIGL $VTUS @ZetaKap
5/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
In LiveCharts today we covered ACHN SAPE NKE XIDE RUTH SPY HSOL CNTF HOTT TLB PLDI RIGL RUTH & HOTT http://stk.ly/iCkl8N
6/28/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
During LiveCharts Today we analyzed the charts on CMI DISH NXPI BUSE AAPL SPY AGYS YGE TLB RIGL & KKD http://bit.ly/ku3Pwl
6/27/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
High-Flying Stocks: 5 Longs & 4 Shorts: AGYS MHLD MGI ENMD ENTG AFFX NR PAET RIGL
6/8/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

MagicDiligence
New MFI stock Rigel Pharma $RIGL. Another dev-stage drug co. Revenue took off in June qtr. Needs research, could be a one-time revenue event
1/21/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

RIGL Rigel Pharmaceuticals, Inc.

RIGL

Rigel Pharmaceuticals, Inc.